NCT01922102 (Brilliance).

Trial name or title	Efficacy and Safety of Ranibizumab 0.5 vs Veteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia (Brilliance)
Methods	Allocation: randomised Endpoint classification: safety/efficacy study Intervention model: parallel assignment Masking: double masked (participant, investigator, outcomes assessor) Primary purpose: treatment
Participants	475 participants Countries: China, Hong Kong, India, Korea, Philippines and Thailand
Interventions	Experimental: Group 1: ranibizumab 0.5 mg driven by visual acuity stability criteria Experimental: Group 2: ranibizumab 0.5 mg driven by disease activity criteria Active comparator: Group 3: verteporfin PDT
Outcomes	Primary outcome measure: change from baseline BCVA to the mean level of BCVA (letters) over all monthly post‐baseline assessments (time frame: month 1 to month 3). Secondary outcome measures: mean level of BCVA (letters); BCVA change (time frame: month 1 to month 6); mean level of BCVA (letters); BCVA change (time frame: 12 months); improvement in BCVA (time frame: 12 months); change in retinal thickness measured on OCT image by reading centre (time frame: 12 months); CNV leakage presence measured on fluorescein angiography image by reading centre (time frame: 12 months); quality of life (time frame: 12 months); number of injections and period (time) between injections (time frame: 12 months); occurrence and incidence of the adverse effects (time frame: 12 months).
Starting date	September 2013
Contact information	Novartis Pharmaceuticals +4163241111
Notes

BCVA: best‐corrected visual acuity; CNV: choroidal neovascularisation; ETDRS: Early Treatment Diabetic Retinopathy Study; OCT: optical coherence tomography; PDT: photodynamic therapy.